🟢 Ocugen is trading 10.45% up today after positive Moderna-Merck Phase 3 cancer-vaccine results

Ocugen is trading +10.45% at $1.48 after biotechnology shares rallied broadly on positive Moderna-Merck Phase 3 cancer-vaccine results.

• Reuters reported the trial success lifted the Nasdaq Biotechnology Index 5.2%; supplied sector data shows XBI up 3.73% on August 19, 2026.
• No company-specific Ocugen announcement was identified; trading activity appears elevated as investors rotate into biotech.